www.fdanews.com/articles/131782-novartis-takes-120-million-hit-from-failed-cancer-drug-trial

Novartis Takes $120 Million Hit From Failed Cancer Drug Trial

November 11, 2010

Swiss pharmaceutical company Novartis AG says it has halted late-stage development of a new drug for lung cancer and will write off $120 million in the fourth quarter as a result.
Star Tribune